Dermatology · Edison, NJ
NPI
1427181270
Since 2007
Specialty
Dermatology
Code 174400000X
Group practices
0
Medicare group memberships
Hospitals
0
Hospital affiliations
4 Progress St, Suite B7
Edison, NJ, 08820
Phone (908) 754-0770
Medicare paid, 2024
$168K
1,487 services
Medicare patients, 2024
436
Average age 78
Drug cost, 2024
$704K
901 prescriptions
Company payments, 2025
$13K
From 19 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Robert M Paull was code 99214 (office e&m - established), 589 times for 270 patients. In total Robert M Paull billed 1,487 services in 58 codes, and Medicare paid $168K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2007-07-08.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 589 | 270 | $101.80 | $60K |
| 99204 Office E&M - New | Office | 125 | 125 | $132.32 | $17K |
| 17004 Destruction Skin Lesion | Office | 92 | 70 | $147.57 | $14K |
| 99213 Office E&M - Established | Office | 87 | 18 | $67.85 | $5,903 |
| 96372 Injection Administration | Office | 57 | 11 | $11.67 | $665 |
| J3301 Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 51 | 14 | $0.77 | $39.25 |
| 99309 SNF E&M | Office | 44 | 32 | $73.13 | $3,218 |
| 17110 Destruction Skin Lesion | Office | 43 | 37 | $96.83 | $4,163 |
| 99305 SNF E&M | Office | 33 | 32 | $100.65 | $3,322 |
| 99215 Office E&M - Established | Office | 28 | 23 | $121.94 | $3,414 |
| 99212 Office E&M - Established | Office | 26 | 22 | $51.56 | $1,340 |
| 11602 Skin Lesion Excision | Office | 23 | 18 | $199.71 | $4,593 |
| 11900 Skin | Office | 17 | 14 | $46.54 | $791 |
| 11642 Skin Lesion Excision | Office | 15 | 14 | $188.87 | $2,833 |
| 99306 SNF E&M | Office | 13 | 12 | $152.66 | $1,985 |
By year: 2022 $212K for 1,825 services; 2023 $187K for 1,648 services; 2024 $168K for 1,487 services.
Medicare prescription drug claims, 2024
In 2024, the drug Robert M Paull prescribed most often to Medicare patients was Triamcinolone Acetonide, with 201 prescriptions and refills. In total Robert M Paull wrote 901 Medicare prescriptions that cost $704K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Triamcinolone Acetonide Generic | 201 | 231 | 119 | $2,511 |
| Ammonium Lactate Generic | 86 | 110 | 41 | $1,831 |
| Clobetasol Propionate Generic | 69 | 80 | 40 | $2,013 |
| Mometasone Furoate Generic | 64 | 72 | 34 | $1,267 |
| Ivermectin Generic | 40 | 42 | Under 11 | $13K |
| Doxycycline Hyclate Generic | 33 | 37 | 19 | $1,110 |
| Metronidazole Generic | 27 | 33 | 14 | $1,614 |
| Enbrel Etanercept | 26 | 26 | Under 11 | $187K |
| Prednisone Generic | 25 | 33 | 22 | $199 |
| Doxepin Hcl Generic | 24 | 34 | Under 11 | $1,887 |
| Seysara Sarecycline Hcl | 21 | 21 | Under 11 | $21K |
| Dupixent Pen Dupilumab | 20 | 24 | Under 11 | $90K |
| Fluocinolone Acetonide Fluocinolone/Shower Cap | 17 | 17 | Under 11 | $579 |
| Ciclopirox Ciclopirox Olamine | 17 | 21 | Under 11 | $379 |
| Valacyclovir Valacyclovir Hcl | 15 | 25 | Under 11 | $334 |
Brand drugs: - claims; generic drugs: 773 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Robert M Paull $13K ($13K in general payments such as food, travel and fees) from 19 companies. The largest payer was Galderma Laboratories, L.P. with $10K.
| Company | Payments | Amount |
|---|---|---|
| Galderma Laboratories, L.P. GALD.SW | 21 | $10K |
| ConvaTec Inc. CTEC.L | 7 | $991 |
| UCB, Inc. UCB.BR | 12 | $361 |
| Novartis Pharmaceuticals Corporation NVS | 8 | $272 |
| Genzyme Corporation SNY | 5 | $197 |
| Abbvie Inc. ABBV | 12 | $147 |
| LEO Pharma Inc. | 3 | $141 |
| Pfizer Inc. PFE | 11 | $136 |
| Mallinckrodt Hospital Products Inc. | 1 | $135 |
| Incyte Corporation INCY | 6 | $104 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.